Egypt Blood Disorder Therapeutics Market

Egypt Blood Disorder Therapeutics Market Executive Summary

Egypt Blood Disorder Therapeutics Market valued at $38 Mn in 2022, projected to reach $75 Mn by 2030 with a 9% CAGR.

A blood disorder is a medical condition characterized by abnormalities in either white blood cells, responsible for immune responses, red blood cells, which carry oxygen, or platelets, crucial for blood clotting. These disorders can lead to various symptoms, including unexplained fatigue and weight loss, impacting the proper functioning of the blood. Many of these conditions are associated with genetic factors, often resulting from mutations in specific gene regions. The severity of blood disorders varies, and their malignancy depends on the underlying causes. Factors such as certain medical conditions, medications, and lifestyle choices can contribute to their development. Treatment options include pharmacotherapy, such as using drugs like romiplostim to stimulate platelet production, antibiotics for white blood cell disorders, and dietary supplements for anemia caused by deficiencies in iron, vitamin B-9, or B-12. In more severe cases, interventions like blood transfusion therapy, chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation may be considered.

Hemophilia A and B are hereditary bleeding diseases that afflict around one in 10,000 girls and one in 50,000 males. In the Egyptian population, thalassemia is the most frequent cause of chronic hemolytic anemia and is associated with a high rate of morbidity and death.

The market is fuelled due to a push from a mix of certain factors like the increased prevalence of Blood Disorders in the country, supported by increased awareness and acceptance and availability of treatment options due to recent technological advancements.

Takeda is a prominent player in the worldwide hemophilia treatment industry, suggesting that it may also be leading this market in Egypt. Pharco Pharmaceuticals is a well-known Egyptian pharmaceutical business having a sizable stake in certain locally made or marketed medications with its expanding array of therapies for blood disorders.

Market Dynamics

Market Growth Drivers

Increasing prevalence: Hemophilia, thalassemia, and sickle cell disease are among the blood diseases that are becoming more common in Egypt, in line with worldwide trends. Numerous variables, including expanding populations, better diagnosis, and more awareness, might be blamed for this growth. In Egypt, there are about 3,000 people who have hemophilia. This figure, together with the population growth, indicates a sizable patient base that is fueling the need for treatments.

Increasing awareness and enhancing diagnosis: In Egypt, more government initiatives and public awareness campaigns are fostering better knowledge and early detection of blood problems. This makes it possible for prompt management and intervention, which raises the need for available treatment choices. The market for therapies is ultimately driven by initiatives like the National Hemophilia Program and Thalassemia Control Program, which increase awareness and improve access to diagnostics.

Treatment and technological developments: Gene therapy and innovative drug delivery methods are two examples of the ongoing treatment options advancements that the global blood disease therapeutics market is seeing. Egypt is gradually gaining access to these developments, which provide optimism for improved patient outcomes and draw capital to the sector.

Market Restraints

Stigma and cultural opinions: Some cultural attitudes about blood diseases have the potential to generate stigma and deter families from getting a diagnosis or receiving treatment. Improving patient outcomes requires dispelling these myths and increasing knowledge. Healthcare professionals must comprehend the potential connections between the use of conventional therapies and traditional medicine practices.

Inadequate healthcare infrastructure: Differences in access to diagnosis and treatment arise from the uneven dispersion of healthcare facilities between urban and rural locations. Patients who live in rural areas may find it difficult to go to specialized care facilities as a result of this. Diagnostic and treatment capacity is further limited by a shortage of qualified healthcare workers, particularly hematologists, and specialists in certain blood diseases.

Excessive treatment costs: Patients and their families are frequently burdened by the exorbitant expense of imported blood disease medications. Access to necessary therapies is hampered by this restricted cost, especially for people without insurance or sufficient service coverage. Manufacturing generic medication locally can be a more affordable option, but building strong manufacturing skills is a difficulty.

Healthcare Policies and Regulatory Landscape

The Egyptian Drug Authority (EDA) is crucial for upholding public health standards by overseeing the regulation of pharmaceuticals and healthcare products in Egypt. Operating under the Ministry of Health and Population, the EDA is responsible for ensuring that drugs available in the country meet rigorous criteria for safety, efficacy, and quality. Its duties span the entire lifecycle of pharmaceutical products, including approval, registration, and ongoing post-market surveillance. A key role of the EDA is to assess and grant marketing authorization to drugs, subjecting them to a comprehensive evaluation of scientific and clinical data to establish their safety and effectiveness before they are permitted to enter the Egyptian market. Following approval, the EDA remains vigilant in monitoring drug safety through activities related to pharmacovigilance. This involves the continuous collection, evaluation, and response to information about adverse effects or any issues related to drugs. The EDA collaborates with healthcare professionals, manufacturers, and the public to maintain a comprehensive and timely reporting system. Furthermore, the EDA engages in international collaborations and adheres to global regulatory standards, staying informed about developments in pharmaceutical science and regulation. Through the enforcement of stringent regulatory measures, the EDA significantly contributes to upholding the quality and safety of pharmaceuticals in Egypt, thereby fostering public confidence in the healthcare system.

Competitive Landscape

Key Players:

• Takeda
• Roche
• Novartis
• Pfizer
• AstraZeneca
• Sanofi
• Grifols
• Octapharma
• Pharco Pharmaceuticals
• EVA Pharmaceuticals